Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease

2017/06/24 by Natalia Mast, Aicha Saadane, Ana C. Valencia‐Olvera +9 · 25 citations
Medicine · #Cholesterol and Lipid Metabolism #Alzheimer's disease research and treatments #Drug Transport and Resistance Mechanisms

paper · doi:10.1016/j.neuropharm.2017.06.026

Citations

• Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients

Cited by

• Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1). [europepmc]
• Intracellular Cholesterol Trafficking and Impact in Neurodegeneration. [europepmc]
• Retinal Vascular Abnormalities and Microglia Activation in Mice with Deficiency in Cytochrome P450 46A1-Mediated Cholesterol Removal. [europepmc]
• Preferential enhancement of GluN2B-containing native NMDA receptors by the endogenous modulator 24S-hydroxycholesterol in hippocampal neurons. [europepmc]
• 24( S ),25-Epoxycholesterol and cholesterol 24S-hydroxylase ( CYP46A1 ) overexpression promote midbrain dopaminergic neurogenesis in vivo . [europepmc]
• Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease Neurons. [europepmc]
• Oxysterol research: a brief review. [europepmc]
• Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases. [europepmc]
• CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice. [europepmc]
• The key genes, phosphoproteins, processes, and pathways affected by efavirenz-activated CYP46A1 in the amyloid-decreasing paradigm of efavirenz treatment. [europepmc]
• In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds. [europepmc]
• Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma. [europepmc]
• Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention. [europepmc]
• Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. [europepmc]
• Oral administration of repurposed drug targeting Cyp46A1 increases survival times of prion infected mice. [europepmc]
• Western Diet Induces Impairment of Liver-Brain Axis Accelerating Neuroinflammation and Amyloid Pathology in Alzheimer's Disease. [europepmc]
• Inflammation and Insulin Resistance as Risk Factors and Potential Therapeutic Targets for Alzheimer's Disease. [europepmc]
• The Controversial Role of 24-S-Hydroxycholesterol in Alzheimer's Disease. [europepmc]
• Abnormal brain cholesterol homeostasis in Alzheimer's disease-a targeted metabolomic and transcriptomic study. [europepmc]
• Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications. [europepmc]
• Brain Renin-Angiotensin System as Novel and Potential Therapeutic Target for Alzheimer's Disease. [europepmc]
• Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor. [europepmc]
• Connecting the Dots Between Hypercholesterolemia and Alzheimer's Disease: A Potential Mechanism Based on 27-Hydroxycholesterol. [europepmc]
• CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer's disease. [europepmc]
• Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development. [europepmc]